**Diaceutics PLC Full Year 2025 Trading Update Summary**
Diaceutics PLC, a leading technology and solutions provider to the pharma and biotech industry, reported strong financial performance for FY 2025, highlighting significant growth and a return to profitability. Key highlights include
**Revenue Growth**Reported revenues of £38.5 million, up 20% year-on-year (YoY), with constant currency growth of 24%, in line with analyst consensus estimates.
**Profitability**Returned to profitability with Adjusted EBITDA exceeding analyst expectations, growing approximately 75% YoY to a margin of 19%.
**Record Order Book**Multi-year order book expanded to over £36.8 million, a 48% YoY increase, providing strong revenue visibility.
**ARR Growth**Annual Recurring Revenue (ARR) increased 21% to over £20.3 million, driven by deeper enterprise-wide customer engagements.
**Customer Expansion**Added three new enterprise-wide customers, including a second PMx commercialisation partnership with a leading US biotech. Now supports 18 of the top 20 global pharma companies and 95 therapeutic brands (up 12%).
**Strategic Progress**Accelerated adoption of AI across the business, enhancing scalability and operational efficiency.
**Outlook**Expects 25% revenue growth in FY 2026, supported by a strong pipeline and continued shift to precision medicine in the industry.
CEO Ryan Keeling emphasized the company’s successful execution of its value-creation strategy, focusing on scale, profitability, and recurring revenues, despite a challenging industry backdrop. Diaceutics remains well-positioned for continued growth and value creation in 2026.